Abstract
Nosocomial infections caused by P. aeruginosa presenting resistance to β-lactam drugs are one of the most challenging targets for antimicrobial therapy. P. aeruginosa harboring acquired mechanisms of resistance, such as production of extended-spectrum β-lactamases (ESBLs) have the highest clinical impact. Hence, this report was designed to investigate the presence of genes codifying for ESBLs among P. aeruginosa isolated from three hospitals in Najaf city. Thirty-six P. aeruginosa isolates were evaluated for the presence of ESBL genes. The isolates presenting ESBL genes were submitted to PCR for molecular evaluation. In all isolates, primary phenotypic test revealed that ESBL phenotype was recognized in isolates (100%) which were expressed resistance to any of the expanded-spectrum cephalosporins and monobactam. Genes encoding ESBLs were detected in 30(83.3%) of isolates. The blaCTX-M was the most prevalent ESBL gene 20(55.6%), followed by blaOXA 18(50.0%) and blaSHV 15(41.7%). These findings raise the concern about the future of antimicrobial therapy, since simultaneous production of ESBLs is known to promote further complexity in phenotypic detection.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
